Background
==========

Chronic Obstructive Pulmonary Disease (COPD) and asthma are complex respiratory diseases involving both genetic and environmental factors (*e.g*. smoking exposure in COPD, allergen exposure in asthma) \[[@B1],[@B2]\]. Using 587 asthma families we have recently fine mapped a 14.4 Mb region on Chromosome 19q13 and identified the urokinase plasminogen activator receptor (*PLAUR*, plasminogen activator receptor, urokinase type, alternative symbols; *UPAR*and *CD87*) gene as an asthma susceptibility gene \[[@B3]\]. Importantly, we also demonstrated that polymorphisms spanning *PLAUR*predict decline in forced expiratory volume in 1 second (FEV~1~) in asthma subjects and determine plasma PLAUR levels \[[@B3]\]. PLAUR plays a key role in the formation of the serine protease plasmin by interacting with urokinase plasminogen activator (PLAU) \[[@B4]\] and has been implicated in many processes including; cell differentiation, proliferation and migration \[[@B5]\]. Plasminogen activator inhibitors (PAI-1 and PAI-2) regulate PLAUR activity \[[@B6]\].

While asthma and COPD are distinct clinical entities, a common feature of both diseases is airway remodelling, *i.e*. deposition of extracellular matrix (ECM) in the submucosa, thickening of the reticularis and smooth muscle hyperplasia \[[@B7],[@B8]\]. From the known biology of PLAUR, this protease receptor is potentially involved in these processes due to its role in matrix metalloproteinase (MMP) and transforming growth factor (TGF)β1 activation and tissue fibrosis \[[@B5]\].

Whole genome linkage analyses using the Boston early onset COPD family cohort has identified linkage to chromosome 19q13 for FEV~1~, FVC and FEV~1~/FVC, LOD 1.40 (59 cM), 1.20 (101 cM), 1.47 (61 cM) respectively \[[@B9]\]. Typing additional markers on 19q13 provided further support for this region *i.e*. FEV~1~and FEV~1~/FVC LOD 1.73 (62 cM), 1.70 (62 cM) which was strengthened by selection of former/current smokers, LOD 3.30 (71 cM) and 1.96 (63 cM) respectively \[[@B10]\]. The *PLAUR*gene is located at 67 cM and based on genetic and biological evidence may be a COPD susceptibility gene. Smoking is associated with an increased decline in FEV~1~and is a major risk factor for the development of COPD \[[@B11]\] therefore we investigated the role of *PLAUR*SNPs in smokers.

The aim of the current study was to test the hypotheses that a) polymorphisms spanning *PLAUR*contribute to COPD susceptibility and severity in smokers and b) that these polymorphisms influence baseline lung function (FEV~1~and FEV~1~/FVC) in smokers. We have genotyped 27 SNPs spanning *PLAUR*in a cohort recruited for COPD or smoking history (n = 992 subjects) and completed a series of association analyses. We provide tentative evidence that polymorphisms spanning *PLAUR*influence baseline lung function but do not support the conclusion that *PLAUR*is a major COPD susceptibility gene in smokers.

Methods
=======

Subjects and Clinical Assessment
--------------------------------

The subjects were recruited from five UK centres for smoking history and/or COPD diagnosis (Table [1](#T1){ref-type="table"}). 537 subjects were collected in Nottingham, Caucasian \> 40 years and smoking \>10 pack years or other centres (n = 455) recruited for spirometry defined COPD confirmed by a physician, Caucasian \> 45 years old and smoking \>10 pack years. The combined population (n = 992) recruited for smoking history or COPD diagnosis were stratified into healthy smokers (n = 176, post bronchodilator (BD, salbutamol) FEV~1~\> 80% and postBD FEV~1~/FVC \> 0.7) and COPD subjects (n = 599, post BD FEV~1~\< 80% and postBD FEV~1~/FVC \< 0.7). Subjects without data or not meeting these criteria were excluded from the case control analyses. COPD severity was investigated using post bronchodilator spirometry, *i.e*. GOLD classification \[[@B12]\] (n = 643, Additional file [1](#S1){ref-type="supplementary-material"}). Ethical approval was obtained from local ethics committees (Nottingham, Sheffield, Manchester, Leicester, Oxford). Informed Consent from all subjects was obtained.

###### 

Baseline characteristics of study cohorts

  ---------------------------------------------------------------------------------------------------------------------
                                Smokers\              Controls\       COPD\           Male Smokers\   Female Smokers\
                                (n = 992)             (n = 176)       (n = 599)       (n = 553)       (n = 431)
  ----------------------------- --------------------- --------------- --------------- --------------- -----------------
  Age in years\                 63.33 ± 10.28 (992)   54.38 ± 9.52    65.96 ± 9.01    64.98 ± 10.01   61.23 ± 10.32
  (mean ± SD)                                                                                         

  Female (%)                    43.8 (984)            56.3            40.4            0               100

  \% predicted FEV~1~\          56.01 ± 28.17 (975)   96.03 ± 12.15   40.31 ± 15.63   52.82 ± 26.87   60.24 ± 29.43
  (mean ± SD)                                                                                         

  FEV~1~/FVC Ratio\             55.3 ± 17.4 (971)     77.3 ± 5.9      46.3 ± 12.6     53.7 ± 17.3     57.5 ± 17.5
  (mean ± SD)                                                                                         

  Post BD % predicted FEV~1~\   59.08 ± 27.14 (885)   99.48 ± 11.72   44.65 ± 15.52   55.34 ± 25.46   64.10 ± 28.55
  (mean ± SD)                                                                                         

  Post BD FEV~1~/FVC Ratio\     55.6 ± 17.7 (873)     79.1 ± 5.5      46.2 ± 12.0     53.2 ± 17.6     58.6 ± 17.6
  (mean ± SD)                                                                                         

  Pack Years\                   43.52 ± 26.05 (969)   32.74 ± 20.04   47.61 ± 27.01   48.72 ± 28.53   36.65 ± 20.66
  (mean ± SD)                                                                                         
  ---------------------------------------------------------------------------------------------------------------------

FEV~1~Forced expiratory volume in one second, FVC forced vital capacity. Number in brackets represents data available for that variable. Continual variables between Controls and COPD groups were compared by independent T-Test, categorical variables by Pearson chi square (all variables p \< 0.0001). Similarly, all variables between males and females were statistically different.

SNP selection and Genotyping
----------------------------

The Human *PLAUR*gene has been sequenced in 46 Caucasian individuals (SeattleSNPs, <http://pga.mbt.washington.edu/>). SNPs were chosen for inferred function or their ability to tag Linkage Disequlibrium (LD) blocks (\[[@B3]\], Table [2](#T2){ref-type="table"}). CEPH genotyping data from the HapMap project (B34) in conjunction with Haploview software (v3.3) was used to identify tagging SNPs within the gene (R^2^0.8, Minor Allele Frequency (MAF) 0.1) or 5\'distal region (R^2^0.75, MAF 0.2) \[[@B13]\]. SNPs were genotyped by Kbiosciences (Hitchin, UK) using genomic DNA. Hardy-Weinberg Equilibrium was assessed using Haploview software \[[@B13]\].

###### 

Gene location and minor allele frequencies of *PLAUR*SNPs genotyped

  **No**.   SNP          Location in PLAUR   Alleles   Selected for:           Smokers   Controls   COPD
  --------- ------------ ------------------- --------- ----------------------- --------- ---------- ---------
  1         rs4803648    3\'UTR              A/T       LDtSNP                  0.20      0.19       0.19
  2         rs4802189    3\'UTR              A/C       LDtSNP                  0.16      0.16       0.15
  3         rs4251953    3\'UTR/intron       G/A       LDtSNP                  0.04      0.05       0.04
  4         rs4251938    3\'UTR/intron       A/G       LDtSNP                  0.12      0.12       0.11
  5         rs4251923    3\'UTR/intron       G/A       3\'UTR                  0.04      0.02       0.04
  6         rs4760       Exon 7              T/C       Pro317/272Leu, LDtSNP   0.16      0.17       0.15
  7         rs2302524    Exon 6              T/C       Lys220/175Arg LDtSNP    0.16      0.16       0.15
  8         rs4251864    Intron 3            T/C       LDtSNP                  0.09      0.09       0.08
  9         rs2239372    Intron 3            G/A       LDtSNP                  0.50      0.48       0.51
  10        rs2283628    Intron 3            T/C       LDtSNP                  0.18      0.18       0.18
  11        rs4251846    Intron 3            C/T       LDtSNP                  0.12      0.11       0.13
  12        rs2239374    Intron 3            C/T       LDtSNP                  0.18      0.19       0.17
  13        rs2286960    Intron 1            C/T       LDtSNP                  0.24      0.28       0.23
  14        rs4251805    5\'UTR-119          G/A       Promoter                0.04      0.03       0.04
  15        rs344781     5\'UTR-466          T/C       Promoter                0.23      0.29       0.29
  16        rs2356338    5\'UTR-649          G/T       Promoter                0.28      0.29       0.29
  17        rs344780     5\'UTR-3545         C/T       Promoter                0.23      0.20       0.22
  18        rs344779     5\'UTR-3666         G/T       LDtSNP                  0.39      0.40       0.37
  19        rs8113334    5\'UTR-6873         T/C       LDtSNP                  0.19      0.19       0.19
  20        rs4493171    5\'UTR-10534        C/T       LDtSNP                  0.22      0.19       0.23
  21        rs7259340    5\'UTR-12331        C/A       LDtSNP                  0.36      0.37       0.34
  22        rs11668247   5\'UTR-20040        C/T       LDtSNP                  0.39      0.43       0.37
  23        rs346043     5\'UTR-20459        T/C       LDtSNP                  0.26      0.26       0.27
  24        rs740587     5\'UTR-22346        T/C       LDtSNP                  0.45      0.49       0.42
  25        rs346054     5\'UTR-30147        C/G       LDtSNP                  0.45      0.47       0.46
                                                                                                    
                                                       Number                  **992**   **176**    **599**

LDtSNP = LD tagging SNP

Statistical Analyses
--------------------

Using SPSS (version 15, SPSS Inc., Chicago, IL) logistic regression analyses were completed for dichotomous traits using additive (*e.g*. AA vs. AC vs. CC), recessive (AA/AC vs. CC) or dominant (AA vs. AC/CC) models. The COPD susceptibility analyses included, age, sex and pack years as covariates (Table [1](#T1){ref-type="table"}) and the GOLD 1 versus 4 analyses included age as a covariate. Unadjusted contingency table analyses were completed using genotype or allele models (GraphPad Prism version 5, San Diego, CA). Linear regression determined the contribution of each SNP to baseline FEV~1~(litres) or FEV~1~/FVC ratio using additive, recessive or dominant models including; age, sex, height and smoking pack years as covariates. Haploview software was used to identify *PLAUR*haplotypes. A p \< 0.01 was considered significant for all analyses.

5\'region analyses
------------------

Basal promoter activity of *PLAUR*has been mapped to 220 bp upstream of the start codon \[[@B14]\]. Using DNA from 31 Caucasian subjects a 4 kb promoter region was amplified and sequenced (Applied Biosystems, UK). SNPs were analysed for transcription factor (TF) binding site changes using online databases as described \[[@B15]\].

Results
=======

Clinical Characteristics and Allele Frequencies
-----------------------------------------------

Baseline features of the COPD cases (n = 599) and controls (n = 176) are shown in Table [1](#T1){ref-type="table"}. As anticipated baseline FEV~1~and FEV~1~/FVC of the smoking controls and COPD cases are significantly different (p \< 0.0001). Comparison of other baseline features between controls and cases identified significant differences for age, sex and pack years, therefore in subsequent analyses we adjusted for these variables. Also shown are the baseline features of male and female smokers which show that females have significantly less smoking exposure and increased lung function compared to male subjects (p \< 0.001). SNPs spanning *PLAUR*were genotyped (Table [2](#T2){ref-type="table"}). Two of the 27 SNPs, rs1994417 and rs4251831 showed deviation from Hardy-Weinberg equilibrium (p = 0.028 and p = 0.004 respectively) in the entire population (n = 992). These SNPs were removed from subsequent analyses.

Haplotype structure
-------------------

The haplotype structure of the *PLAUR*region generated using all data is shown in Figure [1](#F1){ref-type="fig"}. These data revealed that there is some redundancy in the genotyping (as expected) and that there is a block of Linkage Disequilibrium (LD) in the 3\'region, a region of low LD spanning the gene and several blocks of LD in the 5\'region (Figure [1](#F1){ref-type="fig"}).

![**Schematic representation of the *PLAUR*gene and haplotype block structure of *PLAUR*SNPs in smokers**. (A) Schematic representation of the *PLAUR*gene on chromosome 19 illustrating the position of SNPs 1-13 (see Table 2). SNPs 14-25 located in the promoter region/5\'region are omitted for clarity. The *PLAUR*gene is displayed in the reverse orientation to that observed on chromosome 19 (\~40 kb). Exons are depicted as open boxes except for alternatively spliced exon 7 (VIIB, grey, see \[[@B34]\]). (B) Haplotype block structure of all 25 SNPs on Chromosome 19 in smokers (n = 992). The colour of shading represents R^2^(a measure of LD) and numerical values are given (generated using Haploview software \[[@B13]\]). Haplotype blocks were defined using confidence intervals for strong LD D\' 0.7-0.98.](1471-2350-10-112-1){#F1}

*PLAUR*SNPs and COPD susceptibility in smokers
----------------------------------------------

Analyses of the smoking control cohort (n = 176) versus the COPD cohort (n = 599) identified only one SNP meeting statistical significance (p \< 0.01), *i.e*. rs740587(-22346) showed a protective effect for COPD susceptibility (Table [3](#T3){ref-type="table"}). Several other SNPs showed borderline significance including SNPs in intron 1 (rs2286960, protective(P)) and in the 5\'region *i.e*. rs344779(-3666, P), rs11668247(-20040, P) and rs346054(-30147, P). These data provide limited evidence that *PLAUR*SNPs are associated with COPD susceptibility *per se*.

###### 

Risk of COPD in smokers and *PLAUR*SNPs

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                 Controls\   COPD\       Additive   Recessive   Dominant                                                                                                                  
                 (n = 176)   (n = 599)                                                                                                                                                    
  -------------- ----------- ----------- ---------- ----------- ---------- --------- ----------- ---------- --------------- ----------- ---------- --------------- ----------- ---------- ---------------
  rs4803648      112         48          9          381         180        21        0.963       1.01       0.70-1.45       0.313       0.60       0.23-1.61       0.637       1.11       0.72-1.70

  rs4802189      117         47          4          420         151        12        0.964       0.99       0.66-1.48       0.735       0.79       0.20-3.13       0.955       1.01       0.65-1.59

  rs4251953      158         15          1          540         43         2         0.800       0.92       0.49-1.74       0.825       1.38       0.08-24.45      0.742       0.89       0.45-1.77

  rs4251938      133         38          1          466         116        8         0.969       0.99       0.63-1.56       0.656       1.70       0.17-17.27      0.883       0.96       0.59-1.57

  rs4251923      166         8           0          544         44         0         0.598       1.28       0.52-3.16       ND          ND         ND              0.598       1.28       0.52-3.16

  rs4760         122         38          10         429         146        13        0.271       0.81       0.56-1.18       0.106       0.42       0.15-1.20       0.523       0.86       0.55-1.36

  rs2302524      121         54          1          422         149        16        0.691       0.92       0.63-1.37       0.081       7.23       0.78-66.86      0.293       0.79       0.51-1.22

  rs4251864      143         30          1          507         81         5         0.976       1.01       0.61-1.66       0.480       2.38       0.22-26.30      0.876       0.96       0.56-1.64

  rs2239372      48          84          41         150         284        156       0.679       1.06       0.80-1.40       0.857       1.04       0.66-1.66       0.621       1.12       0.71-1.76

  rs2283628      122         43          10         396         172        23        0.822       0.96       0.67-1.38       0.118       0.47       0.18-1.21       0.706       1.09       0.71-1.67

  rs4251846      141         31          3          452         134        8         0.518       1.16       0.74-1.82       0.380       0.50       0.11-2.34       0.340       1.27       0.78-2.08

  rs2239374      115         57          4          401         173        15        0.379       0.85       0.59-1.23       0.785       0.84       0.25-2.88       0.369       0.83       0.54-1.26

  rs2286960      91          71          13         347         215        30        0.022       0.68       0.49-0.95       0.049       0.45       0.20-0.99       0.061       0.68       0.45-1.02

  rs4251805      163         11          0          538         46         1         0.323       1.49       0.68-3.30       ND          ND         ND              0.340       1.48       0.66-3.30

  rs344781       110         50          13         358         191        33        0.719       1.06       0.76-1.49       0.729       0.86       0.38-1.97       0.534       1.14       0.75-1.74

  rs2356338      90          69          16         282         271        38        0.397       1.15       0.83-1.60       0.685       0.85       0.39-1.86       0.215       1.29       0.86-1.92

  rs344780       107         42          11         341         180        31        0.611       1.10       0.77-1.56       0.729       0.86       0.36-2.06       0.422       1.197      0.77-1.86

  rs344779       65          78          33         229         287        74        0.097       0.78       0.58-1.05       0.029       0.54       0.31-0.94       0.437       0.85       0.57-1.28

  rs8113334      120         47          9          397         172        24        0.969       1.01       0.71-1.44       0.478       0.71       0.27-1.85       0.729       1.08       0.70-1.66

  rs4493171      114         53          7          348         215        28        0.204       1.26       0.88-1.79       0.768       1.16       0.44-3.09       0.165       1.34       0.89-2.04

  rs7259340      70          77          26         251         263        69        0.147       0.80       0.60-1.08       0.155       0.65       0.36-1.18       0.299       0.81       0.54-1.21

  rs11668247     67          68          41         241         267        87        0.034       0.74       0.56-0.98       0.022       0.55       0.34-0.92       0.172       0.75       0.50-1.13

  rs346043       94          66          12         305         251        36        0.279       1.20       0.86-1.67       0.836       1.09       0.48-2.48       0.221       1.28       0.86-1.92

  **rs740587**   **54**      **72**      **50**     **206**     **272**    **110**   **0.010**   **0.70**   **0.53-0.92**   **0.016**   **0.56**   **0.35-0.90**   **0.056**   **0.66**   **0.43-1.01**

  rs346054       59          69          48         171         296        124       0.293       0.86       0.66-1.14       0.011       0.55       0.35-0.87       0.509       1.15       0.76-1.77
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

0, 1, 2 represent number of genotypes for major, heterozygote and minor genotypes respectively. For minor allele frequencies in controls versus COPD cases see Table 2. Logistic regression was used to compare genotype frequencies using the additive, recessive, and dominant models with covariates age, sex and pack years included in the model. ND = Not determined (minor allele frequency too low).

*PLAUR*SNPs do not show association with spirometry defined COPD severity
-------------------------------------------------------------------------

Subjects were stratified according to GOLD criteria (Additional file [1](#S1){ref-type="supplementary-material"}) and unadjusted analyses comparing GOLD groups 1, 2, 3 and 4 and extreme severity (GOLD 1 versus 4, adjusted for age) were completed. GOLD Stage 1-4 analyses did not identify any SNPs showing significant association. Adjusted analyses (age) of GOLD Stage 1 and Stage 4 using logistic regression identified rs11668247(5\'UTR-20040) as a protective allele (dominant model OR 0.32 CI 0.14-0.77, p = 0.011) (Additional file [1](#S1){ref-type="supplementary-material"}).

*PLAUR*SNPs influence baseline lung function in smokers
-------------------------------------------------------

In addition to dichotomous trait analyses based on post bronchodilator spirometry we also investigated the role of *PLAUR*SNPs in determining baseline lung function, FEV~1~and FEV~1~/FVC ratio in the entire population (n = 992) (Figure [2](#F2){ref-type="fig"} and Additional file [2](#S2){ref-type="supplementary-material"}). The FEV~1~analyses identified two SNP associations; rs2302524(Lys220Arg) was associated with lower FEV~1~and rs2283628 (intron 3) was associated with higher FEV~1~(Figure [2](#F2){ref-type="fig"}). Both associations were driven by carriers of two variant alleles (recessive model p = 0.006 and p = 0.008 respectively).

![***PLAUR*SNPs are associated with baseline FEV~1~and FEV~1~/FVC**. Regression analysis was used to investigate the association between *PLAUR*SNPs and baseline FEV~1~and FEV~1~/FVC ratio using the additive, recessive or dominant models. Data represent mean ± standard error. Covariates included in the model included age, gender, height and pack years. A = Additive, R = Recessive, D = Dominant models showing p \< 0.01 are presented.](1471-2350-10-112-2){#F2}

In the baseline FEV~1~/FVC analyses three SNPs showed association, *i.e*. rs740587(5\'UTR-22346), rs11668247(5\'UTR-20040) and rs344779(5\'UTR-3666) in the 5\'region were significantly associated with improved FEV~1~/FVC ratio (Figure [2](#F2){ref-type="fig"}, Additional file [2](#S2){ref-type="supplementary-material"}). Borderline significance was also observed for rs344781(5\'UTR-466) and rs2283628(intron 3) for higher baseline FEV~1~/FVC values and rs346043(5\'UTR-204590) and rs2356338(5\'UTR-649) for reduced baseline FEV~1~/FVC values. These data highlight the potential importance of genetic determinants in the 5\'region particularly for the FEV~1~/FVC phenotype. In order to determine if males or females are driving these associations with lung function we completed gender specific analyses for the key associated SNPs (Additional file [2](#S2){ref-type="supplementary-material"}). The baseline features of the male and female only cohorts are shown in Table [1](#T1){ref-type="table"}. These data suggested that both the rs740587(5\'UTR-22346) and rs344779(5\'UTR-3666) associations with FEV~1~/FVC are driven by males as the allele dose effect observed in all subjects is present in male subjects and is lost in females *e.g*. rs344779 FEV~1~/FVC data for males; GG 51.8 ± 1.2 (185), GT 54.5 ± 1.0 (260), TT 59.1 ± 2.0 (66) p = 0.007 versus females; GG 56.8 ± 1.4 (146), GT 57.7 ± 1.2 (195), TT 59.5 ± 1.8 (66), p = 0.531.

*PLAUR*promoter analyses identifies novel SNPs with predicted function
----------------------------------------------------------------------

As several associations were located in the 5\'region we sequenced 4000 bps of the key promoter region (LD block 2, Figure [1](#F1){ref-type="fig"}) in 37 Caucasian subjects to identify novel variation. A further five novel and two reported polymorphism were identified (Additional file [3](#S3){ref-type="supplementary-material"}). The 12 polymorphisms were in high LD (data not shown) which suggested identification of causative polymorphisms will be difficult. Nonetheless, we conducted a bioinformatics analysis and three of these polymorphisms were found to generate binding sites for the E26 transforming sequence (ets) family transcription factor binding sites. Multiple potential changes in transcription factor (TF) binding sites were observed for SNPs in the 5\' distal region *e.g*. alterations in hypoxia inducible factor 1 binding sites (Additional file [3](#S3){ref-type="supplementary-material"}).

Discussion
==========

This study provides preliminary evidence that SNPs within *PLAUR*influence baseline lung function in smokers, however does not support the conclusion that *PLAUR*SNPs contribute significantly to the multiple genetic factors that predispose smokers to develop COPD.

We have previously identified *PLAUR*as an asthma and lung function associated gene and in particular identified the 3\'region (rs4803648, rs4802189), intron 3 (rs2239372) and 5\'region (rs2356338, rs4493171, rs346043) as determinants \[[@B3]\]. *PLAUR*SNPs predicted decline in FEV~1~in asthma subjects and were associated with PLAUR levels in plasma \[[@B3]\] (see Table [4](#T4){ref-type="table"}). These data and the emerging role of PLAUR in tissue remodelling suggested *PLAUR*may also influence COPD susceptibility in smokers. To test this hypothesis we genotyped 27 SNPs spanning *PLAUR*in a cohort of 992 smokers recruited for smoking history and/or COPD diagnosis, 25 SNPs passed quality control. Data from all subjects identified multiple 5\'region LD blocks, a region of low LD spanning the gene and a 3\'region LD block in keeping with our previous data \[[@B3]\].

###### 

Concordance between asthma analyses and the current study

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP          Allele   \*Asthma Susceptibility   Decline in FEV~1~in asthma   \*Serum PLAUR   COPD Susceptibility   COPD Severity\   Baseline FEV~1~   Baseline FEV~1~/FVC
                                                                                                                     (GOLD 1/4)                         
  ------------ -------- ------------------------- ---------------------------- --------------- --------------------- ---------------- ----------------- ---------------------
  rs4803648    T        Risk                      Accelerated                  \-              \-                    \-               \-                \-

  rs4802189    C        Risk                      Accelerated                  \-              \-                    \-               \-                \-

  rs4251953    A        \-                        Accelerated                  \-              \-                    \-               \-                \-

  rs4251938    G        Risk                      \-                           \-              \-                    \-               \-                \-

  rs4251923    A        \-                        \-                           \-              \-                    \-               \-                \-

  rs4760       C        \-                        Slowed                       \-              \-                    \-               \-                \-

  rs2302524    C        Risk                      Accelerated                  \-              \-                    \-               Decreased         \-

  rs4251864    C        \-                        \-                           \-              \-                    \-               \-                \-

  rs2239372    A        Risk                      \-                           Increased       \-                    \-               \-                \-

  rs2283628    C        \-                        \-                           \-              \-                    \-               Increased         \-

  rs4251846    T        \-                        \-                           \-              \-                    \-               \-                \-

  rs2239374    T        \-                        \-                           \-              \-                    \-               \-                \-

  rs2286960    T        \-                        Slowed                       \-              \-                    \-               \-                \-

  rs4251805    A        \-                        \-                           \-              \-                    \-               \-                \-

  rs344781     C        \-                        NA                           \-              \-                    \-               \-                \-

  rs2356338    T        Risk                      Accelerated                  Increased       \-                    \-               \-                \-

  rs344780     T        \-                        \-                           \-              \-                    \-               \-                \-

  rs344779     T        \-                        \-                           \-              \-                    \-               \-                Increased

  rs8113334    C        \--                       \-                           \-              \-                    \-               \-                \-

  rs4493171    T        Protection                \-                           Decreased       \-                    \-               \-                \-

  rs7259340    A        \-                        \-                           \-              \-                    \-               \-                \-

  rs11668247   T        \-                        \-                           \-              \-                    Protection       \-                Increased

  rs346043     C        Risk                      Accelerated                  Increased       \-                    \-               \-                \-

  rs740587     C        \-                        \-                           \-              Protection            \-               \-                Increased

  rs346054     G        \-                        \-                           \-              \-                    \-               \-                \-
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Significant Family Based Association Test (FBAT) results from our previous study.\[[@B3]\] using three asthma family cohorts from Nottingham, Southampton and The Netherlands (n = 587 families). The asthma patients that were probands of the Dutch asthma families (n = 200) were longitudinally followed in the Netherlands for approximately 30 years (1965-1995). FEV~1~decline over time was modelled. FEV~1~forced expiratory volume in one second; FVC forced vital capacity. NA = Not available.

In our first analyses we determined if *PLAUR*SNPs are risk factors for the development of spirometry defined COPD. These data identified only one SNP association (p \< 0.01) *i.e*. rs740587 in the 5\'region was protective however multiple borderline associations were observed particularly for additional SNPs in the promoter/5\'region. We have previously shown that asthma risk alleles span the entire *PLAUR*gene including the 5\'region, intron 3 and 3\'region (Table [4](#T4){ref-type="table"}, \[[@B3]\]). There was no direct concordance between asthma and COPD risk alleles and our data does not support the conclusion that *PLAUR*SNPs are major risk factors for the development of COPD in smokers.

The finding that the only signal for COPD susceptibility maps to the 5\'region is of interest due to the observation that soluble PLAUR is elevated seven fold in the sputum of COPD patients \[[@B16]\] suggesting mechanisms underlying disease association may at least in part involve altered *PLAUR*transcription. In agreement with this hypothesis a recent study identified PLAUR mRNA expression in lung tissue as a marker of COPD and showed a significant correlation between FEF~25-75~(%Pred) and PLAUR mRNA expression (r = -0.44) \[[@B17]\].

COPD severity analyses based on GOLD classification did not identify any SNP showing association. Additional analysis of extremes of severity (GOLD 1 versus 4) again highlighted a role for rs11668247 in the 5\'region in keeping with the COPD susceptibility analyses suggesting a modest influence of the distal 5\'region SNPs.

In order to extend our case/control analyses we investigated the role of *PLAUR*SNPs in determining baseline lung function in this cohort. These analyses identified several significant associations; rs2302524(Lys220Arg) and rs2283628 (intron 3) were associated with lower and higher FEV~1~respectively. rs740587(5\'UTR-22346), rs11668247(5\'UTR-20040) and rs344779(5\'UTR-3666) in the 5\'region were all associated with increased FEV~1~/FVC ratio. Interestingly, several SNPs showed very clear allele dose effects on FEV~1~/FVC ratio *e.g*. rs740587(5\'UTR-22346), providing greater confidence in these data. The magnitude of effect was \~5% change in FEV~1~/FVC between genotypes and so potentially these effects are clinically relevant and surprising for a single SNP in a single gene. Interestingly, two of the SNPs associated with baseline FEV~1~/FVC were also associated with COPD susceptibility and severity respectively, *i.e*. rs740587(5\'UTR-22346) and rs11668247(5\'UTR-20040) in the 5\'region. The rs2302524 (Lys220Arg) association with reduced baseline FEV~1~values is of interest as this variant may be predicted to change the coding sequence of the PLAUR protein and this polymorphism has previously been associated with increased asthma risk and increased decline in FEV~1~in asthma (\[[@B3]\], Table [4](#T4){ref-type="table"}) The Lys220Arg is considered a conservative substitution, however the functional significance of this finding remains to be resolved. Interestingly, our data suggests a potential need for both alleles to be present prior to a physiological effect, *i.e*. a recessive effect.

It is also important to note that the single SNP associations reflect the linkage disequilibrium spanning the *PLAUR*gene *e.g*. rs11668247 and rs740587 are both associated with increased baseline FEV~1~/FVC and these SNPs are in high LD *i.e*. are inherited together more than by chance suggesting they both tag or contribute to the causation mechanism.

For the key associations with lung function we were also interested to determine if males or females were driving the associations and therefore completed gender specific analyses. All baseline features including mean age, smoking pack years and lung function (pre and post bronchodilator FEV~1~and FEV~1~/FVC) were significantly different between the male and female smokers. These data are in keeping with a recent study that examined gender specific differences between subjects with severe emphysema and again identified less severe airway obstruction in females \[[@B18]\]. Our data suggest that the rs740587(5\'UTR-22346) and rs344779(5\'UTR-3666) associations with FEV~1~/FVC are driven by the male subjects as females do not exhibit the allele dose effect on FEV~1~/FVC ratio. Interesting, by selecting male subjects only the magnitude of effect was also increased *i.e*. the range of FEV~1~/FVC between genotypes for rs344779 for all subjects was 5.1% but for males was 7.3%, females 2.7%. This would suggest females do not demonstrate the lower FEV~1~/FVC ratio in carriers of the common alleles at these loci. These data are intriguing and potentially suggest that the effects of the polymorphisms in the 5\'region are unmasked only in males *i.e*. gender specific transcriptional mechanisms. However, it is also feasible that the SNP effects are only identifiable in more severe airway obstruction *i.e*. in the males. This observation requires further investigation.

Cardiovascular disease including; ischemic heart diseases, hypertension and myocardial infarction have also been shown to be a common co-morbidity in COPD \[[@B11]\] and COPD may be an independent risk factor for the development of cardiovascular disease \[[@B19]\]. *PLAUR*levels have been associated with vascular remodelling \[[@B20]\] and monocyte adhesion in acute myocardial infarction \[[@B21]\]. Therefore it is feasible that in the COPD case control analyses we are really testing association with cardiovascular disease not COPD. While we have not formally tested the association between *PLAUR*SNPs and cardiovascular disease outcomes as we do not have this information, this seems unlikely. Our data suggests *PLAUR*SNPs influence baseline lung function in smokers irrespective of the presence or absence of COPD. Similarly, we have identified that *PLAUR*SNPs are determinants of baseline lung function in asthmatic children where clearly cardiovascular disease is not anticipated to confound the analyses \[[@B3]\].

In order to begin to investigate mechanisms underlying associations we have sequenced 4000 bp of the core promoter and identified a further five novel and two reported polymorphisms making a total of 12 polymorphisms in high LD (Additional file [3](#S3){ref-type="supplementary-material"}). Several of these SNPs generate ets family binding sites. c-ets-1 is of particular interest as this transcription factor is induced by oxidative stress *e.g*. H~2~O~2~\[[@B22]\]. Importantly, H~2~O~2~in breath condensate is elevated in COPD \[[@B23]\] and asthma \[[@B24]\]. These data potentially provide the link between the airway environment and expression of PLAUR determined by the presence/absence of SNPs. Interestingly, PLAU and PAI-1 expression are also elevated in sputum from asthma and COPD subjects \[[@B16]\] suggesting the plasminogen system may be augmented in these diseases. Importantly, *PLAU*and *PAI1*transcription is also up regulated by ets-1 \[[@B25],[@B26]\]. Also of interest is the alteration in Hypoxia Inducible Factor (HIF) binding sites due to the presence of a polymorphism (*e.g*. SNP rs11668247(5\'UTR-20040) that was associated with COPD severity and lung function generates a HIF1 site. *PLAUR*transcription has been shown to be increased by HIF1β under hypoxia conditions \[[@B27]\] which may be a mechanism involved in epithelial mesenchymal transition (EMT) \[[@B28]\].

The exact mechanism by which PLAUR contributes to the underlying pathobiology of the airways remains to be resolved, however its role in the generation of plasmin which subsequently leads to ECM degradation, MMP activation, TGFβ1 activation, 5-lipoxygenase activation and cell migration implicate tissue remodelling as a key function \[[@B29],[@B30]\]. The complex role of the PLAU-PLAUR pathway in the airways is illustrated in Figure [3](#F3){ref-type="fig"}. It is important to note that there is accumulating evidence that genetic polymorphism in genes encoding components of the PLAU-PLAUR regulatory network constitute risk factors for the development of COPD *e.g*. polymorphisms spanning Serpin peptidase inhibitor, clade E (*SERPINE2*) have shown significant association with COPD susceptibility, FEV~1~and FEV~1~/FVC \[[@B31]\]. The *SERPINE2*gene encodes a PLAU inhibitor providing further support for the role of the PLAU-PLAUR pathway in COPD pathogenesis.

![**The complex role of the PLAU-PLAUR pathway in the airways**. PLAUR is a complex, multi-domain (D1, 2, 3) molecule and exists as a membrane bound GPI linked protein and in multiple soluble forms. The interaction between PLAU-PLAUR is critical for the conversion of plasminogen to plasmin and is regulated by a series of proteins including; PAI-1, PAI-2 and SERPINE2 which have previously been implicated in COPD pathogenesis \[[@B16],[@B31]\]. Plasmin has many downstream proteolytic effects including those common to remodelling of the airways *e.g*. MMP activation. In addition PLAUR interacts with several membrane receptors leading to the activation of signalling cascades resulting in alterations in; proliferation, migration, adhesion, endocytosis and cytoskeletal changes. PLAUR also exists in multiple soluble forms (sPLAUR) generated by splicing and/or proteolytic cleavage implicated in chemotaxis and interactions with the extracellular matrix \[[@B5],[@B35],[@B36]\].](1471-2350-10-112-3){#F3}

Chromosome 19q13 has previously been investigated for genetic determinants influencing COPD susceptibility. In particular one of five tested SNPs spanning Transforming Growth Factor β1 *TGFB1*(at 41.8 Mbp) was associated with severe COPD in case (n = 304) control (n = 441) analyses and airway obstruction in family (77 pedigrees) analyses (p \< 0.05) \[[@B10]\]. Similarly, one of four tested SNPs within latent transforming growth factor beta binding protein 4, *LTB4P*(at 41.8 Mbp) was associated (p = 0.01) with a densiometric emphysema distribution phenotype (Basal 1/3 lower lobe) \[[@B32]\] but not lung function \[[@B33]\] in 282 and 304 subjects respectively from the National Emphysema Trial. Overall, therefore the evidence that *TGFB1*and *LTB4P*underlie the linkage with FEV~1~and FEV~1~/FVC observed to the region is underwhelming. Importantly, in our asthma analyses we excluded these regions as containing the main dominants of lung function using a combination of linkage and association analyses \[[@B3]\]. However, it is also important to note that in COPD the linkage peak may involve genetic determinants in multiple genes underlying the signal.

This study extends our asthma association and has several strengths including extensive evaluation of polymorphic variation spanning the *PLAUR*region to examine COPD susceptibility and the examination of dichotomous and continual lung function traits. However, the limitations of this study include the absence of an independent replication sample, and that some of the dichotomous analyses were based on small numbers. The low number of controls versus cases in the dichotomous COPD analysis may at least in part explain the lack of concordance in findings generated using the continual lung function traits which provided more clear evidence for association. It is also important to note that the current study examines the role of *PLAUR*SNPs in the development of airway obstruction in smokers and does not test the role of *PLAUR*polymorphisms in non smoking individuals.

Conclusion
==========

We provide preliminary evidence that *PLAUR*SNPs influence baseline lung function in smokers. However, our data does not support a significant role for *PLAUR*SNPs contributing to the multiple genetic factors that predispose smokers to develop COPD.
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